Wednesday, 11 March 2020

Duodenal Cancer Market Size Estimation by Top Manufacturer, Latest Trends and Global industry Forecast 2019 to 2023

Market Scenario
The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new nasal drug delivery technology market, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Duodenal Cancer Market 2023 Forecasts by Global Industry Analysis in 2019 Report

Market Scenario
Duodenal cancer, also known as the small bowel cancer, are caused in the duodenum area of the small intestine. The global duodenal cancer market is expected to grow slowly over the forecast period. It is estimated that the global duodenal cancer market is expected to register a CAGR ~ 3.2% during the forecast period of 2018–2023.
Numerous factors such as the growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Moreover, favorable healthcare expenditures boost the growth of the market. However, stringent government regulation for product approval and the high cost of the treatments may hamper the market growth during the assessment period.
Key players
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Bayer AG are some of the key players in the global duodenal cancer treatment market.
Regional Summary
Geographically, the Americas is anticipated to dominate the global duodenal cancer market owing to a well-developed healthcare sector, rising prevalence of rare and chronic disease and growing healthcare expenditure. According to an article published by, American Society of Clinical Oncology (ASCO) in January 2018, 67% of people diagnosed with duodenal cancer survive it for five years. Europe is expected to hold the second largest position in the global duodenal cancer market. The market growth in this region is attributed to the growing prevalence of chronic diseases, availability of funds for research, and increasing healthcare expenditure. According to Cancer Research UK, 41,804 new cases of bowel cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of diseases and increasing government funding for the healthcare sector. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East & Africa has the least Duodenal Cancer Market Share. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Segmentation
The global duodenal cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into adenocarcinoma, sarcoma, neuroendocrine (carcinoid) tumors, and lymphoma.
The market, by diagnosis, has been segmented into endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.
The market, by treatment, has been segmented into surgery, radiotherapy, and chemotherapy.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The duodenal cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European duodenal cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The duodenal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The duodenal cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora, Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Cubital Tunnel Syndrome Market Size, Share Analysis, Strategies, Revenue and Forecasts to 2023

Market Scenario
Asia Pacific is the fastest growing region in the global market due to the presence of a increasing patient population, continuously developing economies, and increasing need for the better treatment. According to the WHO report published in 2015, Asia's elderly population is projected to reach nearly 923 million by 2050.
The global cubital tunnel syndrome treatment market is expected to grow at a CAGR of 5.6% during forecast period 2017-2023. 
Cubital tunnel syndrome is a condition of increased pressure on the ulnar nerve in the elbow. The ulnar nerve controls muscles and feeling in the hand. Furthermore, it can be caused by direct pressure, stretching, or decreased blood flow to the ulnar nerve. According to the WHO (2014), the incidence of carpal tunnel syndrome is >3 new cases per 1000 persons every year. Women are 3-4 times more susceptible than men. Increasing prevalence of the cubital tunnel syndrome is the major driving factor for the growth of the market. Moreover, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, geriatric population is more likely to suffer from this disease; According to the Aging World in 2015, 562 million (or 8.0 %) were aged 65 and over across the globe, this has increased the prevalence of the diseases and contributed to the growth of the market. However, lack of awareness among people and high cost of surgeries may restrain the growth of the market.
Segmentation
The global cubital tunnel syndrome market is segmented on the basis of causes, treatment, and end users.
On the basis of causes, the market is segmented into injury, noncancerous fatty tumors, bone tumors, inflammation, and others.
On the basis of treatment, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into nerve compression tests, X-ray, electrodiagnostic studies, MRI, and others. The therapy is further segmented into non-operative, and operative. The non-operative is further classified into NSAIDs and steroids.
On the basis of end users, the market is segmented into hospital, retail pharmacy, and other. 
Regional Analysis
The Americas dominates the global cubital tunnel syndrome market owing to large patient population. Additionally, increasing geriatric population, changing lifestyle, and increasing healthcare expenditure have boosted the growth of the market in America. According to the Population Reference Bureau, the number of Americans ages 65 and over is projected to be more than double from 46 million in 2016 to over 98 million by 2060. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.
Europe is the second largest cubital tunnel syndrome market, which is followed by Asia Pacific. Huge geriatric population, availability of funds for research, and government support for research & development projected to drive the market in Europe.
Whereas, the Middle East & Africa owns the least share of  the global cubital tunnel syndrome market due to the presence of poor economy, especially, in Africa region. The market of this region is dominated by the Middle East due to well-developed healthcare sector and huge healthcare expenditure.
Key Players in Global Cubital Tunnel Syndrome Market
The major key players in the global cubital tunnel syndrome market: Eli Lily and Company (US), GlaxoSmithKline PLC (UK), Pfizer Inc., Depomed Inc., Novartis International AG (Switzerland), Johnson & Johnson Services Inc. (US), Bristol-Myers Squibb and Company (US),  Sanofi S.A. (France), Debiopharm Group (Switzerland), Baxter Healthcare Corporation (US), Biogen Idec Inc. (US), Amneal Pharmaceuticals LLC. (US), Amgen, Inc. (US)
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Digital 3D Printing Market SWOT Analysis, Major Key Players Revenue, Analysis and Forecasts to 2025

Digital 3D Printing Market size is expected to register a CAGR of 20.54% to reach USD 5,214.8 Million by 2025. 3D Printing is a process in which physical objects are created by depositing materials in layers based on a digital model. The creation of a 3D printed object is achieved using additive processes. In an additive process, an object is created by laying down successive layers of materials until the object is created. 3D Printing enables to produce complex shapes using less material than traditional manufacturing methods. Each 3D Printing process requires software, hardware, and materials to work together.
Market Dynamics
Increasing applications of Digital 3D Printing in healthcare industry is expected to boost market growth. 3D Printing techniques have empowered medical practitioners, manufacturers of medical devices, as well as researchers due to their use in dental & orthodontic treatments, orthopedic implants, tissue engineering, and drug development. As a result, the increasing benefits of the mentioned applications would boost digital 3d printing market growth. 3D Printing technique is useful to speed up procedures and helps to minimize the trauma faced by patients due to conventional treatment options. Technological advancements in digital 3D Printing, rising public-private funding for 3D Printing activities are the major drivers that contribute to the growth of the digital 3D Printing market.
Segmentation
Global Digital 3D Printing Market analysis is segmented based on Component, Material, Technology, Application and End User.
The market, based on component, has been categorized as system/device and software/services. System/Device held 867.53 market value in 2018
Global digital 3D Printing market, based on material, has been segregated into polymers, metal & alloy, ceramics, and others.
Global digital 3D Printing market trends based on technology, has been segregated into stereolithography, deposition modeling, laser sintering, jetting technology, electron beam melting, and others.
Global digital 3D Printing market based on application has been categorized into dental, prosthetics, orthopedics, medical components, tissue engineering, hearing aids, drug screening, and others.
Global digital 3D Printing market, based on end user, has been segregated into hospitals & surgical centers, dental clinics & laboratories (offices), pharmaceutical & biotechnology companies, and others.
Regional Analysis
Global Digital 3D Printing Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas led the market and accounted for the largest share in 2018, owing to the existence of medical device companies and the rising prevalence of diseases along with increased adoption of treatment by patients. In North America, the US held the largest of the market share in 2018 owing to the presence of major market players, developed healthcare infrastructure, high awareness, and availability of advanced treatment options. For instance, in November 2015, a group of medical researchers from North Carolina’s Wake Forest University developed a method to print the 3D form of custom medications in the configuration of pills. As a result, increasing applications of 3D Printing is expected to drive the market growth.
Europe accounts for the second-largest share in the global digital 3D Printing market owing to the presence of favorable government initiatives & laws and target population base, rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France. Since the ban on animal testing for cosmetics in 2013, the wellness industry had been a significant supporter of 3D Printing in Europe.
Asia-Pacific is estimated to be the fastest-growing market during the forecast period due to the increasing per capita health spending, growing older population base, rising incidence of accidents, and developing the healthcare sector in China, Japan, India, and Australia.
The Middle East & Africa digital 3D Printing market is segmented into two major regions, namely the Middle East and Africa. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others. The Middle East and Africa has less economic developments and extremely low-income due to which the region accounts for the least market share but is expected to grow with the increasing cases of chronic diseases and demand for better treatments in countries.
Key Players
The Prominent Players in the Global Digital 3D Printing Market are Stratasys Ltd (US), 3D Systems, Inc. (US), Carbon, Inc. (US), EnvisionTEC (US), Formlabs (US), ExOne (US), Materialise (Europe), General Electric (US), Micron Dental (US), Renishaw PLC (UK).
Some of the key strategies followed by players operating in the Global Digital 3D Printing Market were acquisitions, expansions, product launches, partnerships, mergers, collaborations, alliances, and product approvals.
  • In June 2019, Materialise received the FDA clearance for the cardiovascular planning software suite. Thus, the suite has helped clinicians to produce patient-specific 3D models for more than 20 years.
  • In November 2019, ExOne introduced the X1 160PRO metal 3D printer for high-volume production of quality parts.
  • In February 2019, EnvisionTEC and AvaDent digital dental solutions announced a new partnership. This partnership offered a complete digital workflow solution for digital dentures, from impressions and digital design to try-in and final restoration.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Worldwide Biosimulation Market Top 10 Players Universal Analysis, Industry Demand and 2023 Forecast

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Biosimulation Market Share, Trends, Research Report - Global Forecast till 2025” Gives industry size, top players and worldwide demand
According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025.  
Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.
The growth of the Global Biosimulation Technology Market is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modeling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period.  
Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices.  
The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.
The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.
The delivery model segment of the market is divided into subscription models and ownership models.
Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.
Key Players
Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Friday, 6 March 2020

Worldwide 4D Printing in Healthcare Market Witness a Remarkable Growth Projected By 2024

Market Overview
Global 4D Printing in Healthcare Market is expected to register a CAGR of 29.4% during the forecast period from 2019 to 2025 and expected to reach USD 30.4 Million by 2025.
In the past decade, there has been increasing use of 3D printing in the field of healthcare. The introduction of 4D printing and its shape-changing material property in the field of dentistry, implants, and prosthetics, among others will further enhance the 3D products used for these applications. The shape-changing property of the material used for 4D printing has been one of the major factors influencing the growth of the market.
Moreover, factors such as increasing research and development, rising investment by chemical companies. These chemical companies are keen on grabbing the opportunity for the development of smart materials in 4D printing, which in turn is directly enhancing the growth of the market.
Factors such as stringent regulatory policies for the approval of 4D printing medical devices market and limited skilled professionals have been major challenges for 4D printing in the healthcare market.  
Market Drivers
  • Increasing application of 4D printing in healthcare verticals such as dentistry, implants, and prosthetics.
    • The dental industry is one of the major applications of 4D printing. Clear aligners have been the most manufactured products via 3D printing in the dental industry.
    • Align technology, the leader in global clear aligners market, accounts for about 80% of the market. The company uses 3D Systems to produce over 1.6 million custom aligners per week.
    • Clear aligners can further be enhanced using 4D printing, as these products require shape altering properties according to the changing structure of the teeth on a weekly basis.
    • 4D printers are also used to manufacture various dental implants, including dental implants, dentures, crowns, & bridges, among others.
    • Increasing prevalence of dental diseases is further influencing the growth of the market. According to the MRFR research study in 2018, it was estimated that oral diseases affected more than 3.7 billion individuals that are around half of the world’s population.
  • Rising research and development
    • A research team from the US in March 2019, invented a new bio-ink that allows to print catalytically active live cells into several self-sustaining 3D geometries. These properties include tunable cell densities, fine filament thickness, and high catalytic productivity.
  • Growing investment by chemical companies
    • Various companies such as BASF Venture Capital GmbH and Evonik Venture Capital have invested in Chinese 3D printing companies
Market Challenges
  • Stringent regulatory policies for the approval of 4D printing medical devices
  • Limited skilled professionals
Segmentation
By Component
  • Software & Services: Software and services accounted for the major market share in 2018. 3D printers have already been installed in numerous healthcare facilities across the globe. However, these machines would require updated software and also various services for the manufacturing of 4D products.
  • Smart Material: Smart Material segment is expected to grow at the fastest growth rate due to continuous advancements for the materials in 4D printing. Investment by chemical companies for the development of smart material is further influencing the market growth.
By Technology
  • Fused Deposition Modeling: Accounted for the largest market share due to its wide choice of raw materials and cost-effective process
  • Direct Inkjet Cure: Expected to grow at the fastest growth rate majorly due to its dimensional accuracy, multi-material, and full-color printing properties
By Application
  • Dental: accounted for the largest market share owing to the use of 4D printing for manufacturing of wide dental products including clear aligners, implants, and dentures among others
  • Prosthetics: Expected to grow at the fastest growth rate due to increasing number of prosthetic procedures, accidental injuries, and sports injuries among others
By End-User
  • Hospitals & Surgical Centers: Accounted for the leading market share owing to the increasing number of hospital & surgical centers. According to a study published by the American Hospital Association, there were 5,534 registered hospitals in the US in 2017.
  • Dental Clinics & Laboratories (Offices): Use of 4D printing in dental clinics & laboratories, brings less complexity to existing procedures. Dental laboratories use 4D printing technologies that allow them to increase competitiveness and production, thus driving the growth of this segment.
By Region
  • Americas: The Americas spearheaded the market in 2018 and is likely to continue to command during the assessment period. This is attributed to the existence of a large number of medical device companies, increasing research and development, and the presence of a large number of noticeable players engaged in manufacturing of 4D printing devices and software
  • Europe: Reported for the second-largest share owing to increasing utilization of 3D & 4D printing in the field of healthcare. According to a study conducted in 2018, it was found that 65% of healthcare providers are implementing new printing technologies for medical products using custom made materials
  • Asia-Pacific: The highest growth rate is attributed to the growing investment by government bodies and private & public companies. For instance, in November 2018, BASF Venture Capital GmbH invested in Chinese 3D printing company Prismlab.
Key Development
  • In January 2019, Dentsply Sirona and Carbon announced a strategic collaboration to revolutionize digital denture materials. This strategic collaboration was announced to deliver denture materials for carbon digital 3D printing production solutions.
Key Players
  • Stratasys Ltd (US)
  • 3D Systems, Inc (US)
  • EnvisionTEC (Germany)
  • Poietis
  • (France) 
  • Organovo Holdings Inc. (US)
  • Materialise NV (Belgium)
  • Dassault Systèmes (France) 

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Global Cell Counting Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2025

Market Forecast

Cell Counting Market is expected to cross USD 12.57 Billion by 2025 at a CAGR of 5.8%.
Market Synopsis
Cell counting is one of the methods for counting cells in life sciences, including medical diagnosis and treatment. The companies operating in this market acquire both organic and inorganic growth strategies to maintain and develop their positions in the market. The increasing funding for stem cell-based research supports the growth of the market.
Market Influencer
Increasing public-private investments and funding in stem cell-based research impact the growth of the cell counting industry positively.
Market Drivers
  • The increasing use of stem cells in various therapeutics is promoting government and private institutes to raise the funding for more development in this area. For instance, in March 2019, the governing Board of the California Institute for Regenerative Medicine (CIRM) funded USD 3.9 million to Ankasa Regenerative Therapeutics to develop the treatment for spinal degeneration which can cause chronic, progressive back pain.
  • The growth of the market is driven by the increasing number of product launches in the global cell counting devices market. Recently, in January 2019 the DeNovix Inc. launched CellDrop Cell Counting without Slides.
  • The cell counting market growth is supported by Increased R&D expenditure in the healthcare industry.
  • Increasing number of stem cell organizations globally support the growth of the market.
  • Rising incidence & prevalence of cancer will support the growth of the market.
Market Restraints
  • The high cost of devices and product recalls are likely to hamper the growth of the cell counting market during the forecast period. Recently in May 2019, Beckman Coulter Inc. recalled DxH800 and DxH600 and DxH 900 hematology analyzers due to risk of inaccurate results.
Cell Counting Market Segmentation
By Product
  • Consumables: The consumables segment includes reagents, assay kits, microplates, and others. The instruments are further segmented into reagents, assay kits, microplates, and others. This segment holds the largest share in the cell counting market due to repeating purchase of consumable products.
  • Instruments: Instruments are used in cell counting methods. The instruments are further segmented into spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Increasing number of product launches will support the growth of the market. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.
By Application
  • Research Application: Cell counting is used for research applications for discovering new medicines. Cell counting has the main application in stem cell research to develop advanced therapy for various diseases. This segment holds the largest share in the cell counting market.
  • Clinical & Diagnostic Applications: Cell counting has a significant role in clinical and diagnosis applications. It is used for diagnosis of various kinds of blood disorders, including infection, anemia, and leukemia.
  • Others: Others include industrial and other commercial applications.
By End-User
  • Pharmaceutical & Biotechnology Companies: The largest segment, pharmaceutical, and biotechnology companies, primarily use cell counting for research purposes. In 2018, the pharmaceutical and biotechnology companies segment held the largest share of the market.
  • Hospitals: Hospitals used cell counting products for the diagnosis of various kinds of diseases such as blood disorders and malaria, among others.
  • Research Institutes: These re involved in specific research activities to develop new and advance treatment for various diseases. Stem cell research institutes are major consumers for cell counting products.
  • Others: These include academic institutes, among others.
By Region
  • Americas: The Americas dominates the global cell counting market owing to an increase in the incidence of cancer, the presence of well-established pharmaceutical and biotechnology industry, availability of technologically advanced products, and significant support from the government in the form of funds and grants.
  • Europe: The key factors driving the market growth are the growing research and development funding and support by government bodies for the healthcare sector, the presence of major manufacturers, and growing healthcare expenditure, among others.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the cell counting market. This is due to developing healthcare infrastructure and rising drug development researchers.
  • Middle East & Africa: It is projected to account for the least share of the global market due to low per capita disposable incomes in the region and limited development of healthcare facilities.
Key Players
  • Thermo Fisher Scientific (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Logos Biosystems, Inc. (South Korea)
  • Olympus Corporation (Japan)
  • Agilent Technologies, Inc. (US)
  • PerkinElmer, Inc. (US)
  • Sysmex Corporation (Japan)
  • Abbott Laboratories (US)


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com